이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Huakang Biomedical Holdings 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chunguang Zhang

최고 경영자

CN¥703.0k

총 보상

CEO 급여 비율	44.7%
CEO 임기	7.1yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	4.7yrs

최근 관리 업데이트

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

Recent updates

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Jun 11

CEO 보상 분석

Chunguang Zhang 의 보수는 Huakang Biomedical Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CN¥6m
Mar 31 2024	n/a	n/a	-CN¥6m
Dec 31 2023	CN¥703k	CN¥314k	-CN¥6m
Sep 30 2023	n/a	n/a	-CN¥5m
Jun 30 2023	n/a	n/a	-CN¥4m
Mar 31 2023	n/a	n/a	-CN¥3m
Dec 31 2022	CN¥689k	CN¥308k	-CN¥3m
Sep 30 2022	n/a	n/a	-CN¥2m
Jun 30 2022	n/a	n/a	-CN¥3m
Mar 31 2022	n/a	n/a	-CN¥4m
Dec 31 2021	CN¥399k	CN¥271k	-CN¥4m
Sep 30 2021	n/a	n/a	-CN¥7m
Jun 30 2021	n/a	n/a	-CN¥8m
Mar 31 2021	n/a	n/a	-CN¥10m
Dec 31 2020	CN¥727k	CN¥250k	-CN¥12m
Sep 30 2020	n/a	n/a	-CN¥9m
Jun 30 2020	n/a	n/a	-CN¥7m
Mar 31 2020	n/a	n/a	-CN¥3m
Dec 31 2019	CN¥349k	CN¥227k	-CN¥284k
Sep 30 2019	n/a	n/a	-CN¥3m
Jun 30 2019	n/a	n/a	-CN¥2m
Mar 31 2019	n/a	n/a	-CN¥377k
Dec 31 2018	CN¥284k	CN¥234k	-CN¥459k
Dec 31 2017	CN¥243k	CN¥183k	-CN¥2m

보상 대 시장: Chunguang 의 총 보상 ($USD 98.09K ) Hong Kong 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 235.49K ).

보상과 수익: 회사가 수익성이 없는 동안 Chunguang 의 보상이 증가했습니다.

CEO

Chunguang Zhang (56 yo)

7.1yrs

테뉴어

CN¥703,000

보상

Mr. Chunguang Zhang is Chief Executive officer at Huakang Biomedical Holdings Company Limited. Mr. Zhang is mainly responsible for business operations and the day-to-day management of Group. Mr. Zhang has...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shuguang Zhang	Chairman of the Board	7.1yrs	CN¥479.00k	27.71% CN¥ 27.3m
Chunguang Zhang	CEO & Executive Director	7.1yrs	CN¥703.00k	데이터 없음
Lai Yin Poon	CFO, Compliance Officer & Executive Director	7.1yrs	CN¥769.00k	0.80% CN¥ 788.0k
Jiaming He	Business Development Director & Executive Director	4.7yrs	CN¥484.00k	데이터 없음
Faat Ting Cheng	Independent Non Executive Director	4yrs	CN¥90.00k	데이터 없음
Yim Yang Chang	Vice Chairman of King Grace Company Limited	no data	데이터 없음	데이터 없음
Kwok Fai Chow	Independent Non-Executive Director	3.8yrs	CN¥90.00k	데이터 없음
Ching Man Chow	Independent Non-Executive Director	1.1yrs	CN¥38.00k	데이터 없음

4.7yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 이사회: 8622 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Huakang Biomedical Holdings 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Chairman of the Board recently sold HK$815k worth of stock

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Recent updates

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.004 loss in 1H 2023)

Huakang Biomedical Holdings Company Limited to Report First Half, 2024 Results on Aug 16, 2024

New minor risk - Share price stability

Most Shareholders Will Probably Find That The Compensation For Huakang Biomedical Holdings Company Limited's (HKG:8622) CEO Is Reasonable

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 18, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.007 million.

Full year 2023 earnings released: CN¥0.014 loss per share (vs CN¥0.008 loss in FY 2022)

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 3.224 million.

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 5.952 million.

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

New minor risk - Shareholder dilution

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.1 million.

Chairman of the Board recently sold HK$815k worth of stock

Huakang Biomedical Holdings Company Limited has filed a Follow-on Equity Offering in the amount of HKD 8.61 million.

Insufficient new directors

Vice Chairman recently sold HK$2.9m worth of stock

Third quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 profit in 3Q 2022)

Huakang Biomedical Holdings Company Limited to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.001 loss in 2Q 2022)

Huakang Biomedical Holdings Company Limited Appoints Chow Ching Man as Independent Non-Executive Director Member of Audit Committee and Nomination Committee

Huakang Biomedical Holdings Company Limited to Report First Half, 2023 Results on Aug 09, 2023

First quarter 2023 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 1Q 2022)

Full year 2022 earnings released: CN¥0.008 loss per share (vs CN¥0.011 loss in FY 2021)

Vice Chairman recently sold HK$101k worth of stock

Less than half of directors are independent

Huakang Biomedical Holdings Company Limited has completed a Follow-on Equity Offering in the amount of HKD 2.60496 million.

Second quarter 2022 earnings released: CN¥0.001 loss per share (vs CN¥0.002 loss in 2Q 2021)

Huakang Biomedical Holdings Company Limited to Report First Half, 2022 Results on Aug 08, 2022

Huakang Biomedical Holdings Company Limited, Annual General Meeting, Jun 17, 2022

First quarter 2022 earnings released: CN¥0.002 loss per share (vs CN¥0.003 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.011 loss per share (vs CN¥0.029 loss in FY 2020)

Huakang Biomedical Holdings Company Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2021

Third quarter 2021 earnings released: CN¥0.001 loss per share (vs CN¥0.001 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.002 loss per share (vs CN¥0.008 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.003 loss per share (vs CN¥0.007 loss in 1Q 2020)

Full year 2020 earnings released: CN¥0.029 loss per share (vs CN¥0.001 loss in FY 2019)

Huakang Biomedical Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 24, 2021

Huakang Biomedical Holdings Company Limited Announces Management Changes

Third quarter 2020 earnings released: CN¥0.001 loss per share

Huakang Biomedical Holdings Company Limited to Report Q3, 2020 Results on Nov 10, 2020

Earnings released

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령